Xcout Intel
Anaveon AG
Anaveon is a late-stage preclinical biotechnology company based in Basel, Switzerland, focused on developing engineered antibodies for immunotherapy.
Subscribe to see Anaveon AG’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Anaveon AG at a glance
Anaveon AG is a biotechnology company headquartered in Switzerland. It has raised at least $121M across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round, Series B, raised $121M in December 2021. Xcout tracks 4 named people at Anaveon AG, including Thaminda Ramanayake (Chief Executive Officer).
Anaveon AG leadership
- Thaminda RamanayakeChief Executive Officer
- Jill JeneChief Business Officer
- Laetitia PouzolChief Scientific Officer
- Thomas P. MathersChairman
Anaveon AG funding rounds
At least $121M raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $121M | 3 named | |
| Series A | Undisclosed | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Anaveon AG competitors
A few of Anaveon AG's closest competitors — see the full list of competitors and alternatives →
Polyneuron Pharmaceuticals is a venture-backed biotech and life sciences company headquartered in Basel, Switzerland. Founded in 2014, the company is pioneering a novel therapeutic approach for the effective and safe treatment of antibody-mediated autoimmune diseases.
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Curon Biopharmaceutical is a clinical-stage biotechnology company developing antibody-based medicines, including bispecific antibodies, for cancer and other serious diseases. It serves patients and healthcare providers through the development of therapeutic biologics, with programs intended for oncology and immunology applications.
Aptevo Therapeutics Inc. is a public, clinical-stage biotechnology company headquartered in Seattle, Washington, focused on developing novel bispecific and trispecific immunotherapies for immuno-oncology.
VAXIMM AG is a biotech company headquartered in Basel, Switzerland, that focuses on developing a new class of cytotoxic immunotherapies and clinical-stage targeted treatments through its subsidiaries.
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Get Anaveon AG's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Anaveon AG in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access